What is claimed is:

1. A method of doing business among two or more entities engaged in research and development, wherein the object of said research and development is the subject of a multinational patent portfolio, said method comprising:

a) providing a territorial distribution of at least some of the rights under said patent portfolio and

b) providing a secondary market for regulatory data and information obtained in one party's research and development whereby it can be utilized by another party in its territory.

2. The method according to Claim 1,

wherein said secondary market comprises granting certain territorial rights in a party's regulatory data and information for an amount compensation that may exceed a first party's cost of development.

3. The method according to Claim 2,

wherein said compensation comprises royalty payments, the rate of which are proportional the commercial advantage conferred on the second party when the regulatory data and information is obtained.

4. The method according to Claim 2,

wherein said object of research and development is a pharmaceutical product.

5. The method according to Claim 4,

wherein the territorial distribution of rights is provided by an exclusive territorial license.

6. The method according to Claim 4,

wherein the parties are independent entities.

7. The method according to Claim 4, which involves at least three parties.

8. A computer implemented method of providing a secondary market for regulatory data and information among two or more entities engaged in research and development where the research and development is the subject of a multinational patent portfolio, comprising:

calculating and recording values related to a territorial distribution of at least some of the rights under said patent portfolio;

developing and storing the regulatory data and information obtained from at least one entity's research and development; and

providing a secondary market by which regulatory data and information obtained from one entity's research and development may be utilized by another entity.

9. The method according to Claim 8,

wherein the step of recording at least some of rights comprises recording values related to an agreement among the entities.

10. The method according to Claim 8,

wherein the step of providing a secondary market comprises an entity calculating values related to having the optional right to use the regulatory data and information obtained by the other entities research and development.

11. The method according to Claim 10,

wherein the optional right can be calculated and exercised at different stages of development of the regulatory data and information obtained by the other entities research and development.

12. A method for allowing a mutual access of regulatory approving data required for obtaining an approval of a government and/or regulations among a plurality of parties

resident in a variety of jurisdictions, the method comprising:

providing a server computer including a regulatory database that stores a plurality of regulatory approving data;

providing a plurality of client computers connected to the server computer via a communication network, each of the client computers having at least an input and output devices and being assigned to each of the parties; and

allowing a first party to access the regulatory approving data in the regulatory database that is possessed by a second party, from the client computer of the first party through the communication network.

13. The method according to Claim 12,

wherein the server computer further includes a patent database storing a patent portfolio having a plurality of patent rights possessed by each of parties; and

wherein each of the regulatory approving data is stored in the regulatory database with connection to each of the patent rights.

14. The method according to Claim 12, further comprising:

inputting accessibility information indicating whether the first party can access the regulatory approving data of

the second party, from the client computer of the second party to the server computer through the communication network; and

storing the accessibility information into the regulatory database with connection to the corresponding regulatory approving data.

15. The method according to Claim 12, further comprising:

inputting a series of compensation conditions for allowing the first party to access the regulatory approving data of the second party, from the client computer of the second party to the server computer through the communication network; and

storing the series of compensation conditions into the regulatory database with connection to the corresponding regulatory approving data.

16. The method according to Claim 15,

wherein the series of compensation conditions includes at least one selected from a group consisting of Research and Development Cost, Amount of Lump-Sum Compensation, Ratio of Lump-Sum Compensation, Ratio of Sales Compensation, Amount of Running Compensation, Ratio of Running Compensation, and Ratio of Sales Running Compensation.

17. The method according to Claim 16,

wherein a pre-marketing approval process is divided into a plurality of distinct development phases so that the regulatory approving data includes a plurality of sub-data different in accordance with the development phase, and

wherein at least one of Amount of Lump-Sum Compensation, Ratio of Lump-Sum Compensation, Ratio of Sales Compensation, Amount of Running Compensation, Ratio of Running Compensation, and Ratio of Sales Running Compensation is different in accordance with the development phase.

18. The method according to Claim 15, further comprising:

inputting an execution instruction from the client computer of the first party to the server computer through the communication network, for obtaining an access right to the regulatory approving data possessed by the second party in consideration of the compensation condition.

19. The method according to Claim 13, further comprising:

licensing at least one of patent rights of the second party stored in the patent database to the first party.

20. The method according to Claim 12,

wherein the subject of the regulatory approving data

is a pharmaceutical product.

21. The method according to Claim 12,

wherein each of the parties is an independent entity.

22. The method according to Claim 12,

wherein at least three parties are involved.